GSK 3342830

Drug Profile

GSK 3342830

Alternative Names: GSK3342830

Latest Information Update: 27 Mar 2017

Price : $50

At a glance

  • Originator Shionogi
  • Developer GlaxoSmithKline; Shionogi
  • Class Anti-infectives; Antibacterials; Cephalosporins
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gram-negative infections

Most Recent Events

  • 15 Mar 2017 GlaxoSmithKline suspends participant recruitment in a phase I trial in Gram-negative infections (In volunteers) in Japan (NCT02751424)
  • 01 Jun 2016 Phase-I clinical trials in Gram-negative infections (In volunteers) in Japan (Parenteral) (NCT02751424)
  • 21 Apr 2016 GlaxoSmithKline plans a first-time-in-human phase I trial in Healthy volunteers in USA and Australia (IV) (NCT02751424)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top